Fount of Information

TriLink BioTechnologies社 July TriLink Messenger







Exosomes Advance from Biological Curiosities to Clinical Applications

This blog highlights two recent examples of mRNA delivery mediated by exosomes for future therapeutic applications: Exosome-based mRNA therapy for treating familial hypercholesterolemia; and exosome-mediated mRNA delivery to induce SARS-CoV-2 immunity. Both reports provide compelling evidence for performing additional studies on the clinical utility of exosomes for mRNA delivery.





Mobilization could replace chemotherapy during treatment with gene-edited stem cells


Dual antigen self-amplifying RNA vaccines promise enhanced protection against SARS-CoV-2

Mobilization promises to replace chemotherapy as a means of bone marrow depletion, improving the lives of patients undergoing hematopoietic stem/progenitor cell gene therapy (HSPC-GT). Find out more in our recent research spotlight.​​​​



​​​​​A dual-antigen self-amplifying RNA vaccine has been shown to induce potent humoral and cellular immune responses that offer protection against emerging variants of SARS-CoV-2. Read on to learn more about the advantages of saRNA vaccines and why accelerating their development is important.






Influenza mRNA Vaccines: Mechanisms and Methodologies


In this first-of-the-series webinar, which GEN and The CRISPR Journal are co-hosting, our distinguished speaker will be Dr. Norbert Pardi, who has been doing some excellent, cutting-edge work on the development of broadly protective mRNA-based influenza vaccines. Not only will he discuss the mechanism of action of mRNA vaccines, Dr. Pardi will also tell us how his laboratory utilized a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine platform to deliver a combination of conserved influenza virus antigens.


Friday July 22, 2022, 11 a.m. ET

Saturday July 23, 2022, 0 a.m. JST





2nd mRNA-Based Therapeutics Summit USA


The most anticipated event of the mRNA calendar, the mRNA-Based Therapeutics Summit is returning for its second year Jul 26 - Jul 28 as the comprehensive, industry-leading meeting for mRNA experts; your one-stop-shop for all your mRNA-based vaccine and therapeutic needs.

You can find TriLink at booth #9.

Join us for a presentation from one of TriLink’s Quality experts.

Quality Attributes to Support the Development of mRNA
Khaled Yamout
Senior Director, Manufacturing & Quality Control
TriLink BioTechnologies


Wednesday July 27, 2022, 2 p.m. ET

Thursday July 28, 2022, 3 a.m. JST



Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。